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In Brief
Ramien et al. interrogate the immune
repertoire in multiple sclerosis (MS)
during pregnancy. They report a shift in
T cell repertoire composition driven by a
small number of ‘‘private’’ clones. This
specific rather than global
immunomodulation may help to explain
the protective effect of pregnancy in
human autoimmunity.
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Identifying T cell clones associated with human auto-
immunity has remained challenging. Intriguingly,
many autoimmune diseases, including multiple scle-
rosis (MS), show strongly diminished activity during
pregnancy, providing a unique research paradigm
to explore dynamics of immune repertoire changes
during active and inactive disease. Here, we charac-
terize immunomodulation at the single-clone level by
sequencing the T cell repertoire in healthy women
and female MS patients over the course of preg-
nancy. Clonality is significantly reduced from the first
to third trimester in MS patients, indicating that the
T cell repertoire becomes less dominated by
expanded clones. However, only a few T cell clones
are substantially modulated during pregnancy in
each patient. Moreover, relapse-associated T cell
clones identified in an individual patient contract
during pregnancy and expand during a postpartum
relapse. Our data provide evidence that profiling
the T cell repertoire during pregnancy could serve
as a tool to discover and track ‘‘private’’ T cell clones
associated with disease activity in autoimmunity.
INTRODUCTION
Identification of relevant T cell clones in complex human autoim-
mune disorders has remained challenging due to the enormous810 Cell Reports 29, 810–815, October 22, 2019 ª 2019 The Authors
This is an open access article under the CC BY-NC-ND license (http://interindividual variability in repertoire composition and diversity
(Hohlfeld et al., 2016a, 2016b). Therefore, cross-sectional
case-control studies have limited power and are unlikely to yield
informative differences at the group level. Rather, identifying
such clones, which are likely ‘‘private’’ (i.e., specific to individual
patients), will require longitudinal assessments over periods
with rapid changes of disease activity and remission. Pregnancy
has a pronounced and clinically relevant impact on maternal
autoimmunity, as reflected by a protective effect of pregnancy
on disease activity of many autoimmune disorders (Barrett
et al., 1999; Confavreux et al., 1998; de Man et al., 2008; Fin-
kelsztejn et al., 2011). In multiple sclerosis (MS), the relapse
rate is reduced by 70%–80% in the third trimester (Confavreux
et al., 1998; Finkelsztejn et al., 2011), which exceeds the effec-
tiveness of many of the currently available therapies for this dis-
ease. Thus, pregnancy could serve as a highly informative
research paradigm to uncover relevant T cell clones in individual
patients with autoimmune disorders.
Pregnancy is also interesting from an evolutionary perspec-
tive, as it poses a challenge to the maternal immune system in
placental mammals to balance prevention of immune attacks
against the fetus while maintaining immunocompetence of the
mother against infections. Strong evolutionary pressure on
reproduction has led to highly specific immune adaptation to
mammalian pregnancy (Samstein et al., 2012) and can thus offer
insights into mechanisms of endogenous immune tolerance.
Many pregnancy hormones have immunomodulatory proper-
ties that could exert nonspecific effects to mediate this phenom-
enon (Gold and Voskuhl, 2016), and pregnancy protection from
autoimmunity in animal models depends on intact endocrine
regulation of T cells (Engler et al., 2017). However, exogenous.
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Pregnancy Shifts Clonal Composi-
tion of the T Cell Repertoire
(A and B) T cell clonality tracked during pregnancy
in PBMCs of female patients with MS (A) and
healthy pregnant women (B). A decrease in clon-
ality indicates that the T cell repertoire is less
dominated by expanded clones and becomes
more evenly distributed.
(C) Degree of absolute and relative change of T cell
clonality in PBMCs from trimester 1 to trimester 3,
contrasted between MS patients and healthy
controls.
(D and E) T cell clonality of CD8+ (D) and CD4+
T cells (E) tracked during pregnancy in MS pa-
tients.
Data are shown as individual data points per
subject (n = 11, MS; n = 12, HC), including median;
p values are derived from a Wilcoxon matched-
pairs signed rank test comparing trimester 1 to
trimester 3 (A, B, D, and E) and a Mann-Whitney U
test comparing groups (C).
See also Figures S1 and S2.application of these hormones does not fully replicate the pro-
tective effect of pregnancy on MS (Pozzilli et al., 2015; Voskuhl
et al., 2016). Moreover, animal models have indicated that cell-
mediated, antigen-specific mechanisms contribute substantially
to the establishment of temporary immune tolerance during
pregnancy (Engler et al., 2017; Kahn and Baltimore, 2010; Mu-
noz-Suano et al., 2012; Rowe et al., 2012). If evidence were
found that pregnancy modulates the human maternal immune
system in a specific rather than a global fashion, then this could
help to unravel antigen-specific tolerance mechanisms, with po-
tential implications for autoimmune disease, transplantation, and
reproductive health.
RESULTS
Pregnancy Alters T Cell Clonality in MS
To test this hypothesis, we employed high-throughput immuno-
sequencing, which allows characterization of the T cell repertoire
at the single-clone level, before pregnancy, at three different
time points during pregnancy (first, second, and third trimester),
and at 3 months postpartum in a cohort of healthy women (n =
12) and a cohort of female MS patients (n = 11). To control for
potential confounders, cases and controls were matched for
age of the mother, sex of the child, and parity (i.e., number of
previous children), with most of the participating women deliv-
ering their first child in this study (see Table S1).
As a measure of T cell repertoire diversity, we first examined
clonal composition in peripheral blood mononuclear cells
(PBMCs) and detected a significant decrease in clonality during
pregnancy in MS patients, but not in healthy controls (Figures 1A
and 1B). MS patients showed significantly stronger downmodu-
lation of T cell clonality from trimester 1 to trimester 3 compared
to controls in terms of both absolute and relative change
(Figure 1C), with large effect sizes (d = 1.03 and d = 1.17 for ab-
solute and relative change, respectively). We further confirmed a
differential effect of pregnancy on clonality using a general linear
model as a sensitivity analysis (main effect for time F = 8.83;degrees of freedom [df] = 2; error df = 20; p = 0.002; effect size
partial h2 = 0.469 as well as a significant time*group interaction
F = 3.95; df = 2; error df = 20; p = 0.036; effect size partial h2 =
0.283). This indicates that duringMS pregnancy, the T cell reper-
toire becomes more evenly distributed and less dominated by
expanded clones. Repertoire analysis in CD4+ and CD8+
T cells confirmed decreasing clonality during pregnancy in MS
patients in both subsets (Figures 1D and 1E).
Of note, no statistically significant differences in T cell clonality
between MS patients and healthy controls (CD8 p = 0.41;
CD4 p = 0.08; PBMCs p = 0.48) were observed at the earliest
time point (trimester 1), further underscoring the large
interindividual variability and the importance of searching for
clones in individuals over time rather than cross-sectionally
between cases and controls. Moreover, tracking T cell repertoire
clonality in n = 3 healthy young non-pregnant women over the
course of 13 months showed some fluctuations over time in
each individual but no discernable pattern (see Figure S1),
lending support to the notion that the pregnancy effect in MS
patients is unlikely to be simply explained by random variability.
The total number of circulating T cells was unaltered during
pregnancy, and few significant changes were observed in rela-
tive CD4+ and CD8+ frequencies or their general phenotype
(see Figure S2). For example, we observed significant reductions
in CD45RO-expressing CD4+ and CD8+ cells of MS patients
during pregnancy (but not healthy controls), indicating that pre-
dominantly antigen-experienced T cells were downmodulated
by pregnancy (Figures S2E and S2F).
Pregnancy Significantly Modulates a Small Number of
Private T Cell Clones
Next, we sought to identify which clones were responsible for
driving the observed changes in T cell repertoire clonality. Pro-
nounced and statistically significant pregnancy effects were
seen for the 25 most abundant clonotypes in each MS patient
(Figures 2A and 2C), but not in healthy controls (Figures 2B
and 2D). Again, absolute as well as relative downregulation inCell Reports 29, 810–815, October 22, 2019 811
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Figure 2. Dynamics of Most Frequent Clo-
notypes in Pregnancy
(A and B) Heatmap plotting the frequency of the
most abundant 25 T cell clonotypes in bulk PBMCs
in each MS patient (A) and each healthy control (B)
tracked over the course of pregnancy.
(C and D) Quantification of clonotypes shown in (A)
and (B), respectively.
(E and F) Degree of absolute (E) and relative
change (F) of cumulative frequency of top 25 clo-
notypes in PBMCs from trimester 1 to trimester 3,
contrasted between MS patients and healthy
controls.
(G) Number of unique clones identified in each MS
patient that significantly contracted from trimester
1 to trimester 3 trimester and re-expanded from
trimester 3 to the postpartum time point (adjusted
for multiple comparisons).
Data are shown as individual data points per
subject (n = 11, MS; n = 12, MS) and median; p
values are derived from aWilcoxon matched-pairs
signed rank test comparing trimester 1 to trimester
3 (C and D) and a Mann-Whitney U test comparing
groups (E and F).
See also Figure S1.cumulative frequency of the top 25 clonotypes from trimester 1
to trimester 3 was significantly larger in MS patients compared
to controls (Figures 2E and 2F).
Then, we identified T cell clones that showed a frequency
pattern mirroring the clinical effect of pregnancy in MS,
i.e., (1) contracting from trimester 1 to trimester 3, and (2) re-
expanding post partum, based on a statistical algorithm and
adjusted for multiple comparisons (‘‘candidate clones’’; see
STAR Methods). We were able to detect clones that followed
this pattern in the majority of patients (9 out of 11; Figure 2G),
with two notable exceptions: one patient who experienced a
relapse during pregnancy (MS41) and another patient (MS23)
treated with a disease-modifying therapy (DMT) (dimethyl
fumarate) directly after delivery. All other patients had between
5 and 40 unique clones that met our statistical criteria. The vast
majority of these clones were found only in a single patient,
indicating that they largely represent private clones (see Data
S1). By applying the pairSEQ approach (Howie et al., 2015),
we were able to successfully identify the corresponding a chain
for 1,774 unique T cell clones including most of the candidate
clones, thereby yielding the T cell receptor (TCR) sequence
described by its V gene, CDR3, and J gene (see Data S1 for812 Cell Reports 29, 810–815, October 22, 2019a complete list of candidate clones and
their frequencies tracked longitudinally
over the course of pregnancy and
postpartum).
T Cell Receptor Sequencing in an
Individual Patient Identifies
Relapse-Associated T Cell Clones
Next, we explored the ability of our
approach to identify and track relapse-
associated clones in an individual pa-tient. Patient MS15 showed the largest number of modulated
clones during pregnancy and postpartum (Figure 2G) and
also experienced a clinical relapse (optic neuritis) at the 3-
month postpartum time point (Figure 3A). This case is particu-
larly informative, as it mirrors the epidemiological pattern of
MS disease activity during pregnancy. Therefore, we first iden-
tified the clonotypes with the highest frequencies during the
postpartum relapse (i.e., top 100 clonotypes) and tracked
them retrospectively over the course of pregnancy. These
relapse-associated clones showed a statistically significant
reduction over the course of pregnancy, with the lowest fre-
quencies in the third trimester (Figures 3B and 3C), observable
in both CD4+ and CD8+ cells. Of note, 23 of the 40 candidate
clones identified for MS15 above (see Figure 2G) were among
the top 100 CD8+ relapse-associated clonotypes. In contrast,
there was no significant pregnancy effect on frequencies of
myelin- or EBNA-1-specific T cells (Figure S4; Data S2).
Moreover, only three EBNA-1-specific (but no myelin-specific)
CD4+ T cell clonotypes were detected in the top 100 relapse-
associated CD4+ T cell clonotypes (see Figure 3). Together,
these data imply that sequencing the TCR during pregnancy
in individual patients can yield a substantial number of
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Figure 3. Tracking of Postpartum-Relapse-Associated Clonotypes
and Antigen-Specific Clonotypes in Patient MS15
(A) Patient MS15 experienced a postpartum relapse at the time of assessment
but had noMS symptoms at any of the time points during pregnancy, therefore
providing an opportunity to track relapse-associated and antigen-specific
clones during pregnancy.
(B and C) Heatmaps tracking the 100 most abundant T cell clonotypes present
during the postpartum relapse over the course of pregnancy are shown for
CD8+ (B) and CD4+ compartment (C) with the corresponding quantifications in
the panels below. In (B) and (C), candidate clonotypes (see Figure 2G) and
EBNA-1-specific clonotypes found among the relapse associated clonotypes
are marked as a black circle or black diamond, respectively.
Data are shown as individual clonotypes (n = 100), including median; p values
are derived from Wilcoxon matched-pairs signed rank test comparing
trimester 1 to trimester 3. HLA genotype of MS15: A *0101/1101; B *0801/
3503; DRB1 *0408/1301; DQA1 *0103/03XX; DQB1 *0304/0603.
See also Figures S3 and S4.potentially relevant clones beyond ‘‘classical’’ putative MS-
related antigens such as myelin or EBV.
DISCUSSION
Together, our data demonstrated that pregnancy in MS signifi-
cantly alters clonal composition of T cells toward a more evenly
distributed repertoire driven by selective downregulation of a few
largely private T cell clones.
Despite evidence that both CD4+ and CD8+ T cell subsets play
a prominent role inMS pathogenesis (Dendrou et al., 2015), iden-
tifying disease-relevant and autoantigen-specific T cells in MS
has remained challenging for both subsets (Hohlfeld et al.,
2016a, 2016b). TCR sequencing approaches have shed light
onto the clonal composition of CNS-infiltrating T cells in MS
(e.g., Jelcic et al., 2018; Planas et al., 2018), but little is knownabout the T cell dynamics in vivo during times of disease activity
and remission. In human subjects in general and pregnant
women in particular, such research is obviously limited to corre-
lational analyses, and we cannot infer causality from our data.
However, our approach illustrates that pregnancy could be a
‘‘window’’ to the dysregulated immune system leading to the
identification of private T cell clones in vivo that are associated
with disease activity in individual patients. Importantly, our anal-
ysis indicates that clones that exhibit the biggest frequency shifts
during times of clinical inactivity (e.g., during pregnancy) versus
inflammatory exacerbation (e.g., postpartum relapse) are typi-
cally private (i.e., unique to individual patients). Moreover,
CD4+ T cells specific to putative disease-related antigens in
MS such as myelin or Epstein-Barr virus (EBV) do not seem to
contribute substantially to the most strongly modulated T cell
clonotypes. This highlights the need for personalized ap-
proaches to identify and track these clones longitudinally in
individual patients rather than cross-sectional case-control
comparisons.
We acknowledge some limitations of our study. Patients
and healthy controls were well characterized and closely
matched on clinical characteristics (but not on human leuko-
cyte antigen [HLA]). However, the sample was still compara-
tively small, and the study should thus be considered explor-
atory. Moreover, the functional characteristics and antigen
specificity of identified clones are presently unknown. Recent
studies have demonstrated pregnancy effects on intracellular
signaling (Aghaeepour et al., 2017) and epigenetic signatures
(Iannello et al., 2019) in the immune system, and such charac-
terizations in unique T cell clones (Han et al., 2014) could help
to better understand the molecular drivers of T cell repertoire
changes. Given that the findings we describe herein allow the
deciphering of the full receptor based on its V gene, J gene,
and CDR3 sequence of the a and b chains of the TCR, such
studies are now within reach. As a result, immune profiling
during pregnancy could open additional avenues for identi-
fying private T cell clones associated with disease activity in
individual patients that could eventually be specifically
targeted.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d LEAD CONTACT AND MATERIALS AVAILABILITY
d EXPERIMENTAL MODEL AND SUBJECT DETAILSB Subjects and recruitment
d METHOD DETAILS
B Blood sampling and processing
B Flow cytometry
B Identification of antigen-specific CD4+ T cells
B Cell purification and DNA extraction
B Immunosequencing
d QUANTIFICATION AND STATISTICAL ANALYSIS
d DATA AND CODE AVAILABILITYCell Reports 29, 810–815, October 22, 2019 813
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celrep.2019.09.025.
ACKNOWLEDGMENTS
This work was supported by the Deutsche Forschungsgemeinschaft
(grants GO1357/8-1, GO1357/8-2, FR1720/8-1, FR1720/8-2, KFO296 Feto-
maternal Immune Cross-Talk to S.M.G. and M.A.F. and grant GO1357/5-2
to S.M.G.).
AUTHOR CONTRIBUTIONS
S.M.G. and M.A.F. conceived the study and acquired funding. C.R., K.P.,
A.W., S.C.R., A.D., A.H., C.H., P.C.A., M.A.F., and S.M.G. planned and con-
ducted patient recruitment, follow-up, and sample collection. S.M.G., E.T.,
A.S., C.S., and M.V. designed the experiments. C.R., K.P., S.G., N.S.,
E.C.Y., M.V., K.C., C.S., R.O.E., and H.S.R. conducted experiments. C.R.,
E.C.Y., S.G., N.S., J.B.E., K.C., and S.M.G. analyzed the data. C.R., E.C.Y.,
K.P., S.G., J.B.E., N.S., A.W., M.V., C.S., H.S.R., A.S., K.C., R.O.E., M.A.F.,
and S.M.G. interpreted the data. C.R., S.G., J.B.E., and S.M.G. designed fig-
ures and tables. S.M.G. wrote the manuscript. All authors critically revised the
manuscript for intellectual content.
DECLARATION OF INTERESTS
E.C.Y., C.S., H.S.R., K.C., M.V., and R.O.E. have or had employment and eq-
uity ownership with Adaptive Biotechnologies. H.S.R. and R.O.E. report pat-
ents related to this work. A.S. is a consultant of Miltenyi Biotec, which has pat-
ents related to this work. The remaining authors declare no competing
interests.
Received: May 31, 2018
Revised: July 10, 2019
Accepted: September 6, 2019
Published: October 22, 2019
REFERENCES
Aghaeepour, N., Ganio, E.A., Mcilwain, D., Tsai, A.S., Tingle, M., Van Gassen,
S., Gaudilliere, D.K., Baca, Q., McNeil, L., Okada, R., et al. (2017). An immune
clock of human pregnancy. Sci. Immunol. 2, eaan2946.
Bacher, P., Schink, C., Teutschbein, J., Kniemeyer, O., Assenmacher, M.,
Brakhage, A.A., and Scheffold, A. (2013). Antigen-reactive T cell enrichment
for direct, high-resolution analysis of the human naive and memory Th cell
repertoire. J. Immunol. 190, 3967–3976.
Barrett, J.H., Brennan, P., Fiddler, M., and Silman, A.J. (1999). Does rheuma-
toid arthritis remit during pregnancy and relapse postpartum? Results from a
nationwide study in the United Kingdom performed prospectively from late
pregnancy. Arthritis Rheum. 42, 1219–1227.
Carlson, C.S., Emerson, R.O., Sherwood, A.M., Desmarais, C., Chung, M.-W.,
Parsons, J.M., Steen, M.S., LaMadrid-Herrmannsfeldt, M.A., Williamson,
D.W., Livingston, R.J., et al. (2013). Using synthetic templates to design an un-
biased multiplex PCR assay. Nat. Commun. 4, 2680.
Confavreux, C., Hutchinson, M., Hours, M.M., Cortinovis-Tourniaire, P., and
Moreau, T.; Pregnancy in Multiple Sclerosis Group (1998). Rate of
pregnancy-related relapse in multiple sclerosis. N. Engl. J. Med. 339,
285–291.
de Man, Y.A., Dolhain, R.J., van de Geijn, F.E., Willemsen, S.P., and Hazes,
J.M. (2008). Disease activity of rheumatoid arthritis during pregnancy: results
from a nationwide prospective study. Arthritis Rheum. 59, 1241–1248.
Dendrou, C.A., Fugger, L., and Friese, M.A. (2015). Immunopathology of mul-
tiple sclerosis. Nat. Rev. Immunol. 15, 545–558.814 Cell Reports 29, 810–815, October 22, 2019DeWitt, W.S., Emerson, R.O., Lindau, P., Vignali, M., Snyder, T.M., Desmarais,
C., Sanders, C., Utsugi, H., Warren, E.H., McElrath, J., et al. (2015). Dynamics
of the cytotoxic T cell response to a model of acute viral infection. J. Virol. 89,
4517–4526.
Engler, J.B., Kursawe, N., Solano, M.E., Patas, K., Wehrmann, S., Heckmann,
N., L€uhder, F., Reichardt, H.M., Arck, P.C., Gold, S.M., and Friese, M.A. (2017).
Glucocorticoid receptor in T cells mediates protection from autoimmunity in
pregnancy. Proc. Natl. Acad. Sci. USA 114, E181–E190.
Finkelsztejn, A., Brooks, J.B., Paschoal, F.M., Jr., and Fragoso, Y.D.
(2011). What can we really tell women with multiple sclerosis regarding
pregnancy? A systematic review and meta-analysis of the literature.
BJOG 118, 790–797.
Gold, S.M., and Voskuhl, R.R. (2016). Pregnancy and multiple sclerosis: from
molecular mechanisms to clinical application. Semin. Immunopathol. 38,
709–718.
Han, A., Glanville, J., Hansmann, L., and Davis, M.M. (2014). Linking T-cell re-
ceptor sequence to functional phenotype at the single-cell level. Nat. Bio-
technol. 32, 684–692.
Hohlfeld, R., Dornmair, K., Meinl, E., and Wekerle, H. (2016a). The search for
the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lympho-
cytes as pathogenic effectors and therapeutic targets. Lancet Neurol. 15,
198–209.
Hohlfeld, R., Dornmair, K., Meinl, E., and Wekerle, H. (2016b). The search for
the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and an-
tibodies in the focus of reverse-translational research. Lancet Neurol. 15,
317–331.
Howie, B., Sherwood, A.M., Berkebile, A.D., Berka, J., Emerson, R.O., William-
son, D.W., Kirsch, I., Vignali, M., Rieder, M.J., Carlson, C.S., and Robins, H.S.
(2015). High-throughput pairing of T cell receptor a and b sequences. Sci.
Transl. Med. 7, 301ra131.
Iannello, A., Rolla, S., Maglione, A., Ferrero, G., Bardina, V., Inaudi, I., De Mer-
canti, S., Novelli, F., D’Antuono, L., Cardaropoli, S., et al. (2019). Pregnancy
epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis.
Front. Immunol. 9, 3075.
Jelcic, I., Al Nimer, F., Wang, J., Lentsch, V., Planas, R., Jelcic, I., Madjovski,
A., Ruhrmann, S., Faigle, W., Frauenknecht, K., et al. (2018). Memory B cells
activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. Cell
175, 85–100.e23.
Kahn, D.A., and Baltimore, D. (2010). Pregnancy induces a fetal antigen-spe-
cific maternal T regulatory cell response that contributes to tolerance. Proc.
Natl. Acad. Sci. USA 107, 9299–9304.
Kirsch, I., Vignali, M., and Robins, H. (2015). T-cell receptor profiling in cancer.
Mol. Oncol. 9, 2063–2070.
Munoz-Suano, A., Kallikourdis, M., Sarris, M., and Betz, A.G. (2012). Regula-
tory T cells protect from autoimmune arthritis during pregnancy.
J. Autoimmun. 38, J103–J108.
Planas, R.,Metz, I., Martin, R., and Sospedra,M. (2018). Detailed characteriza-
tion of T cell receptor repertoires in multiple sclerosis brain lesions. Front. Im-
munol. 9, 509.
Pozzilli, C., De Giglio, L., Barletta, V.T., Marinelli, F., Angelis, F.D., Gallo, V., Pa-
gano, V.A., Marini, S., Piattella, M.C., Tomassini, V., et al. (2015). Oral contra-
ceptives combined with interferon beta in multiple sclerosis. Neurol. Neuroim-
munol. Neuroinflamm. 2, e120.
Robins, H.S., Campregher, P.V., Srivastava, S.K., Wacher, A., Turtle, C.J.,
Kahsai, O., Riddell, S.R., Warren, E.H., and Carlson, C.S. (2009). Comprehen-
sive assessment of T-cell receptor b-chain diversity in alphabeta T cells. Blood
114, 4099–4107.
Robins, H., Desmarais, C., Matthis, J., Livingston, R., Andriesen, J., Reijo-
nen, H., Carlson, C., Nepom, G., Yee, C., and Cerosaletti, K. (2012).
Ultra-sensitive detection of rare T cell clones. J. Immunol. Methods 375,
14–19.
Rowe, J.H., Ertelt, J.M., Xin, L., and Way, S.S. (2012). Pregnancy imprints
regulatory memory that sustains anergy to fetal antigen. Nature 490,
102–106.
Samstein, R.M., Josefowicz, S.Z., Arvey, A., Treuting, P.M., and Rudensky,
A.Y. (2012). Extrathymic generation of regulatory T cells in placental mammals
mitigates maternal-fetal conflict. Cell 150, 29–38.Sherwood, A., Desmarais, C., and Emerson, R.O. (2015). TCRB time cour-
se.https://clients.adaptivebiotech.com/pub/healthy-adult-time-course-TCRB.
Voskuhl, R.R., Wang, H., Wu, T.C., Sicotte, N.L., Nakamura, K., Kurth, F.,
Itoh, N., Bardens, J., Bernard, J.T., Corboy, J.R., et al. (2016). Estriol com-
bined with glatiramer acetate for women with relapsing-remitting multiple
sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol.
15, 35–46.Cell Reports 29, 810–815, October 22, 2019 815
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
CD195 (CCR5) PE (HEK/1/85a) Biolegend Cat# 313707; RRID:AB_345307
CD45RO PerCP/Cy5.5 (UCHL1) Biolegend Cat# 304221; RRID:AB_1575041
CD28 PE/Cy7 (CD28.2) Biolegend Cat# 302926; RRID:AB_10644005
CD197(CCR7) APC (TG8/CCR7) Biolegend N/A
CD8 APC/Cy7 (RPA-T8) Biolegend Cat# 301016; RRID:AB_314134
CD4 V500 (RPA-T4) BD Cat# 560768; RRID:AB_1937323
CD62L Pacific BlueTM (DREG-56) Biolegend Cat# 304826; RRID:AB_2186977
CD195(CCR5) FITC (HEK/1/85a) Biolegend Cat# 313705; RRID:AB_345305
CD25 PE (BC96) Biolegend Cat# 302606, RRID:AB_314276
CD127 PerCP/Cy5.5 (A019D5) Biolegend Cat# 351322; RRID:AB_10897104
CD39 PE/Cy7 (A1) Biolegend Cat# 328212; RRID:AB_2099950
CCR2 APC (TG5/CCR2) Biolegend N/A
CD28 pure - functional grade (15E8) Miltenyi Biotec Cat# 130-093-375; RRID:AB_1036134
CD40 pure - functional grade (HB14) Miltenyi Biotec Cat# 130-094-133; RRID:AB_10839704
CD3 pure - functional grade (OKT3) Miltenyi Biotec Cat# 130-093-387; RRID:AB_1036144
CD4 APC (Vit4) Miltenyi Biotec Cat# 130-092-374; RRID:AB_871680
Anti-Biotin FITC (Bio3-18E7) Miltenyi Biotec Cat# 130-090-857; RRID:AB_244257
CD69 APC-Vio770 (FN50) Miltenyi Biotec Cat# 130-099-907; RRID:AB_2661137
CD14 VioGreen (TU¨K4) Miltenyi Biotec Cat# 130-096-875; RRID:AB_2660175
CD8 VioGreen (BW135/80) Miltenyi Biotec Cat# 130-096-902; RRID:AB_2660905
CD20 VioGreen (LT20) Miltenyi Biotec Cat# 130-096-904; RRID:AB_2660933
CD154 VioBlue (5C8) Miltenyi Biotec Cat# 130-096-217; RRID:AB_10829767
TNF-a PE (cA2) Miltenyi Biotec Cat# 130-091-651, RRID:AB_244203
CD45RA Pacific BlueTM (HI 100) Biolegend Cat# 304123; RRID:AB_2174122
CD27 FITC (O323) Biolegend Cat# 302806; RRID:AB_31429
Chemicals, Peptides, and Recombinant Proteins
PepTivator MOG Miltenyi Biotec Cat# 130-096-770
PepTivator MBP Isoform 1 Miltenyi Biotec Cat# 130-096-763
PepTivator PLP Miltenyi Biotec Cat# 130-097-274
PepTivator EBV EBNA-1 Miltenyi Biotec Cat# 130-093-613
RPMI-1640 medium + GlutaMAX GIBCO, Thermo Fisher Scientific Cat# 11554516
human AB serum Sigma Aldrich Cat# H4522-100ML
TexMACS medium Miltenyi Biotec Cat# 130-097-196
IL-2 (Proleukin) Novartis N/A
Inside Stain Kit Miltenyi Biotec Cat# 130-090-477
Critical Commercial Assays
Anti-human CD4 particles BD Imag, BD Bioscience Cat# 557767; RRID:AB_398629
Anti-human CD8 particles BD imag, BD Bioscience Cat# 557766; RRID:AB_398628
DNeasy Blood and Tissue Kit QIAGEN Cat# 69506
ImmunoSEQTM Assay Adaptive Biotechnologies; Carlson et al.,
2013; Robins et al., 2012; Robins et al.,
2009
N/A
PairSEQTM Assay Adaptive Biotechnologies; Howie et al.,
2015
N/A
(Continued on next page)
e1 Cell Reports 29, 810–815.e1–e4, October 22, 2019
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
CD154 MicroBead Kit, human Miltenyi Biotec Cat# 130-092-658
CD3 MicroBeads, human Miltenyi Biotec Cat# 130-050-101
MS columns Miltenyi Biotec Cat# 130-042-201
Deposited Data
Longitudinal MS and HC pregnancy TCR
seq data
This paper https://doi.org/10.21417/B7B012
Time course healthy female TCR seq data Sherwood et al., 2015 https://doi.org/10.21417/B7J01X
Software and Algorithms
R version 3.2 R Project for Statistical Computing RRID:SCR_001905; http://www.r-
project.org/
FlowJo FlowJo RRID:SCR_008520; https://www.
flowjo.com
GraphPad Prism 5 GraphPad Software RRID:SCR_002798; https://www.
graphpad.com/
Uniform Manifold Approximation and
Projection (UMAP) Plug-in to FlowJo
FlowJo arXiv:1802.03426; https://www.flowjo.
com/exchange/
ImmunoSEQTM Analyzer 2.0 Adaptive Biotechnologies N/A; https://www.adaptivebiotech.
com/products-services/immunoseq/
immunoseq-analyzer/
ImmunoSEQTM Analyzer 3.0 Adaptive Biotechnologies N/A; https://www.adaptivebiotech.
com/products-services/immunoseq/
immunoseq-analyzer/LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, StefanM.
Gold (stefan.gold@zmnh.uni-hamburg.de). This study did not generate new unique reagents or materials.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Subjects and recruitment
MS Patients were recruited through the Multiple Sklerose Tagesklinik of the Universita¨tsklinikum Hamburg-Eppendorf. Healthy con-
trols were recruited through the Klinik f€ur Geburtshilfe und Pra¨natalmedizin, Universita¨tsklinik Hamburg-Eppendorf. The study was
approved by the local ethics commission (Ethik-Kommission der Hamburger A¨rztekammer; Approval No: PV3558, No: PV3694). All
participants gave informed consent and were remunerated for time and effort. Female MS patients were selected from our study
cohort based on sample availability and confirmed MS diagnosis. Healthy women were selected to match age, sex of the child,
and parity (see Table S1). All mothers had single pregnancies. All MS patients were free of disease-modifying therapies (DMTs) during
pregnancy. At the pre-pregnancy time point, one patient received DMT (interferon b-1a; MS42) and one patient was in relapse man-
agement and received steroid treatment (1mg for 3 days; blood sampled before second infusion; MS23). All but two patients (MS 41
DMT (interferon b-1a), MS23 DMT (dimethyl fumarate)) remained free of DMTs until after the last blood sample (three months post
partum). Details on DMTs are provided in Table S1.
METHOD DETAILS
Blood sampling and processing
Blood samples of MS patients were collected before, during and after pregnancy: before conception (Pre), in trimester 1 between
week 10 and 14 of gestation (Tri1), in trimester 2 between week 22 and 24 (Tri2), in trimester 3 between week 30 and 36 (Tri3) and
three months post partum (Post). Healthy controls gave blood samples at the same time points during pregnancy and post partum
(but pre-pregnancy samples were not available for controls). Blood was collected in EDTA coated tubes (Sarstedt, N€umbrecht, Ger-
many) and peripheral blood mononuclear cells (PBMCs) were isolated by a 30min gradient centrifugation at 863xg using Biocoll
Separating Solution (Biochrom, Berlin, Germany), followed by two washing steps. Cells were then cryopreserved in RPMI medium
(PAN-Biotech, Aidenbach, Germany) with 25% fetal calf serum (Biochrom) and 10% DMSO (AppliChem, Darmstadt, Germany)Cell Reports 29, 810–815.e1–e4, October 22, 2019 e2
and stored in liquid nitrogen until further analysis. During experimental procedures, the experimenters were not blinded. A differential
blood count was performed on full blood using a Coulter AC*T Diff (Beckmann Coulter, Brea, CA, USA).
Flow cytometry
After a short resting period, fresh blood samples were incubated with antibody cocktail (CD45RA PB (HI 100), CD27 FITC (O323),
CCR5 PE (HEK/1/85a), CD45RO PerCP/Cy5.5 (UCHL1), CD28 PE/Cy7 (CD28.2), CCR7 APC (TG8/CCR7), CD8 APC/Cy7
(RPA-T8), (all Biolegend, San Diego, CA, USA); CD4 V500 (RPA-T4; BD Bioscience, San Jose´, CA, USA)) or (CD62L PB (DREG-
56), CCR5 FITC (HEK/1/85a), CD25 PE (BC96), CD127 PerCP/Cy5.5 (A019D5), CD39 PE/Cy7 (A1), CCR2 APC (TG5/CCR2), (all Bio-
legend); CD4 V500 (RPA-T4; BD Bioscience)) in the dark at room temperature, then erythrocytes were lysed with BD FACS Lysing
Solution (BD Bioscience) and washed twice in PBS (520xg, 5min, 4C). Samples weremeasured on a FACSCanto II (BD Bioscience).
Data were analyzed using FloJo software (FlowJo, LLC., Ashland, OR, USA). Dimensionality reduction was performed on a concat-
enated dataset after downsampling lymphocytes positive for either CD8, CD4, or both to 10000 events (approx. 750000 events).
Uniform Manifold Approximation and Projection (UMAP) plugin from FlowJo was used (Euclidian distance, nearest neighbor: 15
and minimum distance: 0.5, channels: CD4, CD8, CCR5, CD45RO, CD45RA and CCR7). To visually display change over time,
another downsampling to 20000 events of the concatenated dataset was performed. Classical manual gating was performed for
depicted T cell subsets.
Identification of antigen-specific CD4+ T cells
Fresh PBMCs from patient MS15 were isolated by density gradient centrifugation (Biocoll, Biochrom) and resuspended at a concen-
tration of 2x107/ml in RPMI 1640 medium supplemented with GlutaMAX (GIBCO, Thermo Fischer Scientific Darmstadt, Germany)
and 5% (v/v) human AB serum (Sigma Aldrich, Schnelldorf, Germany). Myelin and EBNA-1-specific CD4+ T cells were enriched ac-
cording to the Antigen-Reactive T Cell Enrichment (ARTE) protocol (Bacher et al., 2013) with modifications as described. 9x107 cells
were stimulated for 6 h with MOG, MBP1 and PLP peptide pools and 3.8x107 cells were stimulated with EBNA-1 peptide pool (each
0.6 nmol/peptide/ml) in the presence of 1 mg/ml CD40 (clone HB14) functional grade pure antibody (all Miltenyi Biotec, BergischGlad-
bach, Germany). Activated CD154+ T cells were magnetically enriched (CD154 MicroBead Kit and MS columns, Miltenyi Biotec) and
stained with CD4 APC (Vit4), CD154 (via anti-Biotin-FITC, Bio3-18E7), CD69 APC-Vio770 (FN50), CD14 VioGreen (TU¨K4), CD8 Vio-
Green (BW135/80) and CD20 VioGreen (LT20) antibodies (all Miltenyi Biotec). To further increase purity, antigen-reactive CD4+/
CD154+/CD69+ T cells were FACS-sorted (Influx cell sorter; BD Biosciences). About 2500 (myelin) or 1000 (EBNA-1) isolated cells
were expanded for 8 days with 2.5x106 irradiated allogenic feeder cells in a 48-well plate in TexMACS medium (Miltenyi Biotec) sup-
plemented with 30 ng/ml anti-CD3 (OKT-3; Miltenyi Biotec), 200 IU/ml IL-2 (Proleukin; Novartis, N€urnberg, Germany), 100 IU/ml Peni-
cillin, 100 mg/ml Streptomycin (both Sigma Aldrich), 20 mM b-Mercaptoethanol (GIBCO, Themo Fischer Scientific) and 5% human AB
serum. The cells were split and medium was replenished as needed. After resting in RPMI 1640 medium + 5% human AB serum for
2 days, expanded cells were restimulated for 7 hours with the initial myelin antigens or EBNA-1 in the presence of 1 mg/ml CD28 func-
tional grade pure antibody (15E8; Miltenyi Biotec) and autologous CD3-depleted PBMCs in a 1:1 ratio (CD3 MicroBeads, Miltenyi
Biotec). After 3 hours, 1 mg/ml Brefeldin A (Sigma Aldrich) was added. The cells were stained with CD4 APC and CD14 VioGreen,
fixated and permeabilized (Inside Stain Kit, Miltenyi Biotec) and stained intracellularly with CD154 VioBlue (5C8) and TNF-a PE
(cA2, both Miltenyi Biotec). Activated CD154+/TNF-a+ T cells and non-activated CD154‒/TNF-a‒ T cells were FACS-sorted. Cells
at several steps throughout the expansion procedure were shock-frozen in liquid nitrogen (1.5x105 cells at time points 5/6 and
5x105 cells at time points 1-4, see Figure S3) for later DNA isolation and TCR sequencing as described below.
Cell purification and DNA extraction
PBMCs were thawed, counted and separated into 3 parts: at least 106 PBMCs were directly pelleted and shock frozen, the other 2
parts were used for magnetic cell sorting of CD4+ and CD8+ cells. CD4+ and CD8+ cells were isolated separately in parallel proced-
ures using positive selection kits (BD Imag; BD Bioscience) according to the manufacturer’s instructions (using 30mL of magnetic
particles for up to 107 cells). After isolation, CD4+ and CD8+ cells were pelleted and shock-frozen. To extract DNA, cell pellets
were thawed and processed with the DNeasy Blood and Tissue Kit (QIAGEN, Hilden, Germany), following the manufacturer’s pro-
tocol for tissue, then stored at 20C until shipment.
Immunosequencing
Immunosequencing of the CDR3 regions of human TCRb chains was performed using the ImmunoSEQTM Assay (Adaptive Biotech-
nologies, Seattle, WA, USA). Extracted genomic DNA was amplified in a bias-controlled multiplex PCR, followed by high-throughput
sequencing. Sequences were collapsed and filtered in order to identify and quantitate the absolute abundance of each unique TCRb
CDR3 region for further analysis as previously described (Carlson et al., 2013; Robins et al., 2009, 2012).
TCRa3 TCRb pairs were identified using the PairSEQTM Assay. Here, the TCRa and TCRb loci are immunosequenced on a single
96 well plate, using the ImmunoSEQTM Assay as described above. This yields an occupancy vector with 96 components for each
TCRa and TCRb rearrangement. Comparison with the null probabilities given by random subset sampling allow statistically confident
pairing of TCRa and TCRb with sufficiently similar occupancy vectors, and a multiple testing correction procedure involving a simu-
lated null distribution enforces a false discovery rate of 1% (Howie et al., 2015).e3 Cell Reports 29, 810–815.e1–e4, October 22, 2019
QUANTIFICATION AND STATISTICAL ANALYSIS
Clonality was defined as 1- Pielou’s evenness (Kirsch et al., 2015) and was calculated on productive rearrangements by: 1+
ðP
N
i
pi log2ðpiÞ =log2ðNÞÞ where pi is the proportional abundance of rearrangement i and N is the total number of rearrangements.
Clonality values range from 0 to 1 and describe the shape of the frequency distribution: clonality values approaching 0 indicate a
very even distribution of frequencies, whereas values approaching 1 indicate an increasingly asymmetric distribution in which a
few clones are present at high frequencies. Changes in TCRclonality, clonotype frequencies, lymphocyte frequencies and phenotype
during pregnancy were tested using Wiloxon matched-paris signed rank test (trimester 1 versus trimester 3). Group differences of
absolute and relative change of clonality and the cumulative frequency of top clonotypes was performed using Mann-Whitney-U
test. In the afore mentioned tests, P-values < 0.05 were considered statistically significant. Statistical details of each experiment
are reported in the respective figure legends. Statistical analysis was performed in R version 3.2. and GraphPad Prism 5 (GraphPad
Software, San Diego, CA, USA). So called ‘‘candidate clones’’ were defined as clones that had significantly lower frequency in
trimester 3 compared to trimester 1 and significantly higher frequency post partum compared to trimester 3, i.e. these clones con-
tracted from trimester 1 to trimester 3 and expanded from trimester 3 to post partum. These clones were identified based on a sta-
tistical method performed as described (DeWitt et al., 2015), with minor variations to statistical parameters involving implantation of a
minimum total template count filter of 5 templates, and incorporation of multiple testing correction with the Benjamini-Hochberg (BH)
method. After multiple-testing correction, the threshold of significance was a < 0.01 on the BH adjusted P-values.
Clonotype frequency data was exported with ImmunoSEQ Analyzer 3.0 (Adaptive Biotechnologies) as frequency of all unique pro-
ductive TCRb CDR3 amino acid sequences. Candidate clonotypes frequencies (see Data S1 and S2) were extracted with Immuno-
SEQ Analyzer 2.0 (Adaptive Biotechnologies), displaying frequency of clones as percentage of all rearrangements.
DATA AND CODE AVAILABILITY
The complete data from this study are available for download and analysis at an open-access, shareable repository (ImmuneACCESS).
Data may be accessed using the following link after creating a free account: https://doi.org/10.21417/B7B012.
Data on time course of healthy females is accessible at: https://doi.org/10.21417/B7J01X (Sherwood et al., 2015). No new code
was generated in this study.Cell Reports 29, 810–815.e1–e4, October 22, 2019 e4
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Figure S1: T-cell repertoire fluctuations in three young healthy non-pregnant females 
over the course of 13 months.  
(A) Time course of T-cell repertoire clonality in PBMCs of healthy non-pregnant women. 
Heatmap (B) and cumulative frequencies (C) shown for the 100 most abundant clonotypes in 
each woman over time. Refers to Figure 1 and Figure 2. 
  
 
Figure S2: Pregnancy changes in lymphocyte numbers, frequencies and phenotype.  
Overall count of T-cells within the PBMC pool shown for MS patients (A) and healthy 
controls (B) throughout pregnancy. Overview of multi-parametric phenotypic T-cell analysis 
(C) visualized by dimensionality reduction (UMAP) throughout pregnancy for MS patients 
(top) and healthy controls (bottom). Darker coloring indicates higher abundance of cells 
falling into this cluster. Staining intensity of the clusters for each marker within the UMAP is 
displayed in (D), orange representing highly positive populations, blue the negative 
populations. Frequencies of major T-cell subsets in MS patients (E) and healthy controls (F) 
throughout pregnancy. In all panels, individual values for each subject (A: n = 11, B: n = 12, 
C-F: n = 11) and the median are shown; P values are derived from Wilcoxon matched-pairs 
signed rank test comparing trimester 1 to trimester 3. Refers to Figure 1. 
 
 
  
  
 
Figure S3: Experimental setup for expansion and characterization of EBV and myelin-
specific CD4+ T-cells in patient MS15.  
(A) Workflow of T-cell stimulation with EBNA-1 or myelin peptide pool and subsequent 
expansion of the antigen specific cells before re-stimulation. Circled numbers indicate the 
time points at which samples were taken for sequencing and the corresponding sample IDs in 
the immuneACCESS public database (https://doi.org/10.21417/B7J01X). Checks for feeder 
cell contamination in EBNA-1 and myelin pool restimulated samples are shown in (B) and 
(C), respectively. Minimal clonotype overlap (green dots) indicates negligible feeder 
contamination. Refers to Figure 3 and Figure S4. 
 
 
 
 
 
 
  
 
 
Figure S4: EBNA-1 and myelin-specific clonotypes tracked over time in patient MS15.  
Frequencies of all clonotypes reactivated by EBNA-1 (A) or the myelin pool (B) and found in 
at least one time point throughout pregnancy in the CD4+ compartment are displayed (see 
sequenced samples 6, Figure S3A). Three EBNA-1 specific clonotypes were found among 
the top 100 most frequent CD4+ clonotypes during relapse in MS15 (see Figure 3). Data are 
represented as individual clonotypes of patient MS15 and median. P values are derived from 
Wilcoxon matched-pairs signed rank test comparing trimester 1 to trimester 3. Refers to 
Figure 3 and Figure S3. 
  
Table S1: Demographic and clinical characteristics of mothers with MS and healthy control 
mothers matched for age, parity, and sex of child. For MS patients, history of disease 
modifying therapy (DMT) is displayed, for healthy controls this is not applicable (-). Related 
to STAR*Methods. 
ID age parity* sex of child DMT naive DMT prior to Pre time point 
Treatment-free 
time prior to Pre 
time point 
(months) 
DMT between 
Pre and Tri1 
Time between 
Pre and Tri1 
(months) 
MS.1 28 1 f Yes - - No 16 
HC.21 29 1 f - - - - - 
MS.13 34 1 m Yes - - No 3 
HC.3 31 1 m - - - - - 
MS.15 25 1 f Yes - - No 3,5 
HC.17 21 1 f - - - - - 
MS.23 28 1 m No IFN/glatiramer acetate 2 No 15 
HC.10 31 1 m - - - - - 
MS.25 29 1 m Yes - - No 6 
HC.5 24 1 m - - - - - 
MS.31 33 1 f No IFN 4 No 16 
HC.16 33 1 f - - - - - 
MS.33 32 1 f No IFN 1 No 12 
HC.13 29 1 f - - - - - 
MS.40 40 1 f Yes - - No 2 
HC.12 36 1 f - - - - - 
MS.41 32 1 f No IFN, azathioprine 6 No 8 
HC.18 33 1 f - - - - - 
MS.42 34 1 f No IFN 5,5 Yes (IFN) 13 
HC.6 31 1 f - - - - - 
MS.52 35 2 m Yes - - No 5 
HC.2 36 2 m - - - - - 
HC.7 30 1 m - - - - - 
 
* 1 = pregnant with first child during the study, 2 = pregnant with second child during the study 
 
